Ipsen SA

SAN DIEGO--(BUSINESS WIRE)--Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. Under the terms of the agreement, Ipsen has obtained an exclusive option to license the program globally following successful drug candidate nomination. Upon exercise of the option, Ipsen would assume responsibility for global development and commercialization. “We are delighted to join forces with Origami whose pioneering work in developing protein degraders targeting genetic neurodegenerative diseases represents a powerful new frontier in rare neuroscience,” said Steve Glyman, SVP and Head of Neuroscience Research & Development, Ipsen. “Their approach aligns seamlessly with Ipsen’s strong rare neuroscience heritage and expertise in small‑molecule innovation, enabling us to advance first‑ and best‑in‑class therapies for people living with debilitating conditions where treatment options remain limited.” “This collaboration with Ipsen is a strong validation of Origami’s science and of the potential of targeted protein degradation to address the root causes of rare genetic neurodegenerative diseases,” said Beth Hoffman, Ph.D., Chief Executive Officer and Founder of Origami Therapeutics. “Ipsen brings deep expertise in rare neuroscience and global development, making them an ideal partner as we advance this program toward the clinic. Together, we share a commitment to translating cutting-edge biology into meaningful therapies for patients who currently have limited or no treatment options.” Origami’s small-molecule protein degraders, developed using its proprietary ORICISION™ technology platform, are designed to leverage the body’s natural protein disposal mechanisms to selectively eliminate disease-causing proteins while preserving normal protein function. Under the terms of this new collaboration and option agreement, the team at Origami is eligible to receive payments aligned to pre-agreed development, regulatory and commercial milestones, including an upfront payment for the option and research collaboration, plus potential royalties. About Origami Therapeutics Origami Therapeutics is a biotechnology company developing small-molecule protein degraders and correctors for neurodegenerative diseases, including Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other dementias. The company is currently advancing its lead program ORI-003 in Huntington’s disease. Origami Therapeutics aims to develop therapies with the potential to slow or halt disease progression and meaningfully improve quality of life for patients and their families. For more information, visit www.origamitherapeutics.com.

Ipsen Board of Directors Peter Guenter Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026. PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position. Peter Guenter holds nearly 40 years of experience as an executive leader in the global pharmaceutical industry. Most recently, he served as Chief Executive Officer of Merck Healthcare and member of the Executive Board of Merck Group from 2021 to 2025. Prior to that, Peter was CEO at Almirall, where from 2017 onward, he led the company’s strategic refocus on medical dermatology. He also spent more than 20 years at Sanofi across numerous leadership roles and joined Sanofi's Executive Committee in 2013. Throughout his career, Peter has had a proven track record of success in partnerships, and excellence in execution. Beyond these executive leadership roles, Peter is an active contributor to a variety of boards across the healthcare and private equity landscapes. Following this co-optation, Ipsen’s Board of Directors will remain composed of 14 directors: seven women 1 and seven men, including five independent directors and two directors representing employees. At the next Shareholders’ meeting, there will be a request for ratification of this decision, which would remain in effect for the remainder of Henri Beaufour’s term of office, until the 2027 Shareholders’ meeting. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com . Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . 1 Representing 42%, the Directors representing the employees not being taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce Attachments Ipsen PR_BoD Peter Guenter_29012026 Ipsen Board of Directors Peter Guenter

Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: 💰 Public offering roundup: 📜 Tribunal sides with Ipsen in dispute with Galderma: The International Chamber of Commerce has dismissed Galderma’s claim in the arbitration proceedings, which relates to Ipsen’s decision to end an R&D deal between the companies that dates back to 2014. The agreement was focused on neuromodulators. Galderma said the decision has no impact on its commercial neuromodulator franchise. — Ayisha Sharma 💵 PAQ expands Series B: The Burlington, MA-based startup boosted its Series B to $77 million. It was initially $39 million in May 2025. The biotech also dosed the first patient in a trial of its pan-KRAS degrader called PT0511. — Kyle LaHucik 🤝 Resolve M Therapeutics leaves stealth: The Cambridge, MA-based biotech was created through a “strategic collaboration” between Johnson & Johnson Innovation and General Inception. The company is focused on treating chronic inflammatory and autoimmune disorders. — Ayisha Sharma